Tradegate
03.09.26 | 09:00
0,048 Euro
+4,40 % +0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,043 | 0,048 | 03.09. | |
| 0,043 | 0,048 | 03.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | Hemostemix Inc (2): Hemostemix talks up enrolment to hear Shankle | 2 | Stockwatch | ||
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 20.08. | Hemostemix Inc.: Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell Under LARTA | 538 | Newsfile | Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell (ACP-01) today at 12:00 EST... ► Artikel lesen | |
| 12.08. | Hemostemix Inc (2): Hemostemix names longevity trial principal investigator | 2 | Stockwatch | ||
| 12.08. | Hemostemix Inc.: Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell Longevity Clinical Trial | 962 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr.... ► Artikel lesen | |
| 31.07. | Hemostemix Inc (2): Hemostemix closes $322,250 second tranche of placement | 1 | Stockwatch | ||
| 31.07. | Hemostemix Inc.: Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026 | 677 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche... ► Artikel lesen | |
| 29.07. | Hemostemix Inc (2): Hemostemix drafts VesCell phase 1 trial protocol | 3 | Stockwatch | ||
| 28.07. | Hemostemix Inc.: Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell's Excellent Results | 639 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative... ► Artikel lesen | |
| 23.07. | Hemostemix Inc (2): Hemostemix grants options to buy 6.28 million shares | 6 | Stockwatch | ||
| 22.07. | Hemostemix Inc.: Hemostemix Grants Stock Options | 434 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 09.07. | Hemostemix Inc (2): Hemostemix files commercialization application | 3 | Stockwatch | ||
| 08.07. | Hemostemix Inc.: Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain | 563 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine... ► Artikel lesen | |
| 26.06. | Hemostemix Inc (2): Hemostemix closes $360,000 first tranche of placement | 2 | Stockwatch | ||
| 26.06. | Hemostemix Inc.: Hemostemix Closes $360,000 First Tranche of Private Placement | 421 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche... ► Artikel lesen | |
| 17.06. | Hemostemix Inc.: Hemostemix' $1,000,000 Private Placement and Update | 600 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches... ► Artikel lesen | |
| 09.03. | Hemostemix Inc.: Hemostemix Leadership Attending Abundance360 Summit | 538 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026... ► Artikel lesen | |
| 03.02. | Hemostemix Inc.: Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships | 337 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 16.01. | Hemostemix Inc.: Hemostemix Receives FDA Support for Its Basket Protocol Approach | 640 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 31.12.25 | Hemostemix Inc.: Hemostemix Closes $480,000 Private Placement at $0.12 per Share | 456 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 23.12.25 | Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 | 607 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,274 | -0,97 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| QIAGEN | 37,470 | -1,80 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| VALNEVA | 2,999 | +0,77 % | Valneva mit Rückenwind: Analysten sehen über +150% Kurspotenzial | ||
| EPIGENOMICS | 0,900 | 0,00 % | PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet | DJ PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet
Unternehmensmitteilung für den Kapitalmarkt
Epigenomics AG: Kapitalerhöhung in Höhe von EUR... ► Artikel lesen | |
| NOVAVAX | 8,870 | -0,22 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 265,00 | +0,04 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,530 | -0,08 % | 2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 | ||
| CO.DON | 0,013 | -37,50 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| OCUGEN | 1,166 | +0,69 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,130 | 0,00 % | Summit Therapeutics Stock Rises 11% | ||
| ALUMIS | 11,360 | 0,00 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| CG ONCOLOGY | 74,33 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,950 | 0,00 % | Dyne to present preclinical data on four DMD therapies | ||
| CLIMB BIO | 14,590 | 0,00 % | Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 12,750 | -0,23 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
HEMOSTEMIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,40 % bei einem Aktienkurs von 0,048 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.